<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35338991</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1618-095X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>100</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title>
          <ISOAbbreviation>Phytomedicine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Implication of IGF1R signaling in the protective effect of Astragaloside IV on ischemia and reperfusion-induced cardiac microvascular endothelial hyperpermeability.</ArticleTitle>
        <Pagination>
          <StartPage>154045</StartPage>
          <MedlinePgn>154045</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2022.154045</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0944-7113(22)00123-4</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Myocardial ischemia-reperfusion (I/R) causes damage to coronary capillary endothelial barrier and microvascular leakage (MVL), aggravating tissue injury and heart dysfunction. However, the effective strategy for protecting endothelium barrier of cardiac vasculature remains limited.</AbstractText>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aimed to explore the effect of Astragaloside IV (ASIV) on coronary MVL after cardiac I/R and the underlying mechanism.</AbstractText>
          <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Sprague-Dawley (SD) rats were used for assessment of the efficacy of Astragaloside IV in protection of myocardial I/R injury, while human cardiac microvascular endothelial cells were applied to gain more insight into the underlying mechanism.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Sprague-Dawley rats with or without pretreatment by ASIV at 10 mg/kg were subjected to occlusion of left coronary anterior descending artery followed by reperfusion. Endothelial cells were exposed to hypoxia and re-oxygenation (H/R). The distribution of junction proteins was detected by immunofluorescence staining and confocal microscope, the content of junction proteins was detected by Western blot, the level of adenosine triphosphate (ATP) was detected by ELISA, and the signal pathway related to permeability was detected by siRNA infection. The fluorescence intensity of FITC-albumin and FITC-Dextran was measured to evaluate the permeability of endothelial cells.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">ASIV exhibited protective effects on capillary damage, myocardium edema, albumin leakage, leucocyte infiltration, and the downregulated expression of endothelial junction proteins after I/R. Moreover, ASIV displayed ability to protect ATP from depletion after I/R or H/R, and the effect of ASIV on regulating vascular permeability and junction proteins was abolished once ATP synthase was inhibited. Notably, ASIV activated the insulin-like growth factor 1 receptor (IGF1R) and downstream signaling after reoxygenation. Knocking IGF1R down abolished the effect of ASIV on restoration of ATP, junction proteins and endothelial barrier after H/R.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ASIV was potential to prevent MVL after I/R in heart. Moreover, the study for the first time demonstrated that the beneficial role of ASIV depended on promoting production of ATP through activating IGF1R signaling pathway. This result provided novel insight for better understanding the mechanism underlying the potential of ASIV to cope with cardiac I/R injury.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier GmbH.. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Ke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Tasly Microcirculation Research Center, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Tasly Microcirculation Research Center, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Se-Qi</ForeName>
            <Initials>SQ</Initials>
            <AffiliationInfo>
              <Affiliation>Tasly Microcirculation Research Center, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yu-Ying</ForeName>
            <Initials>YY</Initials>
            <AffiliationInfo>
              <Affiliation>Tasly Microcirculation Research Center, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Bai-He</ForeName>
            <Initials>BH</Initials>
            <AffiliationInfo>
              <Affiliation>Tasly Microcirculation Research Center, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Tasly Microcirculation Research Center, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Xin-Rong</ForeName>
            <Initials>XR</Initials>
            <AffiliationInfo>
              <Affiliation>Tasly Microcirculation Research Center, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Shu-Ya</ForeName>
            <Initials>SY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Xiao-Hong</ForeName>
            <Initials>XH</Initials>
            <AffiliationInfo>
              <Affiliation>Tasly Microcirculation Research Center, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Jing-Yu</ForeName>
            <Initials>JY</Initials>
            <AffiliationInfo>
              <Affiliation>Tasly Microcirculation Research Center, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Chun-Shui</ForeName>
            <Initials>CS</Initials>
            <AffiliationInfo>
              <Affiliation>Tasly Microcirculation Research Center, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China. Electronic address: chunshuipan@pku.org.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Jing-Yan</ForeName>
            <Initials>JY</Initials>
            <AffiliationInfo>
              <Affiliation>Tasly Microcirculation Research Center, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tianjin, China. Electronic address: hanjingyan@bjmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Phytomedicine</MedlineTA>
        <NlmUniqueID>9438794</NlmUniqueID>
        <ISSNLinking>0944-7113</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012503">Saponins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3A592W8XKE</RegistryNumber>
          <NameOfSubstance UI="C052064">astragaloside A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004727" MajorTopicYN="N">Endothelium</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015428" MajorTopicYN="Y">Myocardial Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015424" MajorTopicYN="N">Reperfusion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012503" MajorTopicYN="Y">Saponins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014315" MajorTopicYN="Y">Triterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ATP synthesis</Keyword>
        <Keyword MajorTopicYN="N">Astragaloside IV</Keyword>
        <Keyword MajorTopicYN="N">Cell–cell junctions</Keyword>
        <Keyword MajorTopicYN="N">Insulin-like growth factor 1 receptor</Keyword>
        <Keyword MajorTopicYN="N">Microvascular leakage</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>20</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35338991</ArticleId>
        <ArticleId IdType="doi">10.1016/j.phymed.2022.154045</ArticleId>
        <ArticleId IdType="pii">S0944-7113(22)00123-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
